A Phase II Trial of Suberoylanilide Hydroxamic Acid for Recurrent or Primary Refractory Hodgkin's Lymphoma.

Trial Profile

A Phase II Trial of Suberoylanilide Hydroxamic Acid for Recurrent or Primary Refractory Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2013

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2011 Planned end date (Oct 2007) added as reported by ClinicalTrials.gov.
    • 08 Aug 2007 Status change from suspended to in progress.
    • 19 Jan 2007 Status change from Recruiting to Suspended
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top